标签归档：ff

SGN-2FF

发表于由

SGN-2FF  纯度: ≥99.0%

SGN-2FF 是一种有效的，具有口服活性的岩藻糖基化抑制剂，抑制岩藻糖基转移酶 (fucosyltransferase) 的活性，具有抗肿瘤活性。

SGN-2FF

SGN-2FF Chemical Structure

CAS No. : 2089647-47-0

规格 价格 是否有货 数量
10 mM * 1 mL in Water ￥1980 In-stock
5 mg ￥1800 In-stock
10 mg ￥2880 In-stock
25 mg ￥5760 In-stock
50 mg ￥9200 In-stock
100 mg ￥14750 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SGN-2FF 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Covalent Screening Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library

生物活性

SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity[1].

IC50 & Target

Fucosyltransferase[1]
体外研究
(In Vitro)

SGN-2FF (2-Fluorofucose) is an inhibitor of fucosylation, inhibits cellular fucosylation by depleting the fucosylation substrate GDP-fucose, and by direct inhibition of fucosyltransferases, and leads to the production of afucosylated glycoproteins including antibodies. SGN-2FF activates human T cells in an antigen-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

SGN-2FF exhibits antitumor activity in multiple mouse tumor models, showing substantial tumor growth delay. SGN-2FF elevates the protective effect of a lymphoma vaccine in a syngeneic mouse model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

166.15

Formula

C6H11FO4
CAS 号

2089647-47-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (300.93 mM; Need ultrasonic)

H2O : 36.67 mg/mL (220.70 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 6.0187 mL 30.0933 mL 60.1866 mL
5 mM 1.2037 mL 6.0187 mL 12.0373 mL
10 mM 0.6019 mL 3.0093 mL 6.0187 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Stephen C. Alley, et al. Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms. Cancer Res 2017;77(13 Suppl).

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制Neuropeptide FF (5-8),Morphine Modulating Peptide, C-Terminal Fragment 编码 [152050-35-6]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Neuropeptide FF (5-8),Morphine Modulating Peptide, C-Terminal Fragment
编码 [152050-35-6]
别名 Neuropeptide FF (5-8),Morphine Modulating Peptide, C-Terminal Fragment
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） PQRF-NH2
序列（三字母缩写） H-Pro-Gln-Arg-Phe-NH2?(acetate salt)
基本描述 Intestinal peptide that stimulates contraction of gut smooth muscle. The motilin receptor has not been cloned yet, but motilin-receptor agonists appear to be potent prokinetic agents for the treatment of dysmotility disorders.
溶解度
分子量 545.64
化学式 C25H39N9O5
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Neuropeptide FF (5-8),Morphine Modulating Peptide, C-Terminal Fragment 编码 [152050-35-6]
Figures Neuropeptide FF (5-8),Morphine Modulating Peptide, C-Terminal Fragment 编码 [152050-35-6]
Reference N.A.Elshourbagy et al., J. Biol. Chem., 275, 25965 (2000) S.-K.Han et al., Proc. Natl. Acad. Sci. USA, 99, 14740 (2002)
C端
N端
化学桥

多肽定制Neuropeptide FF; F-8-F-NH2 编码 [99566-27-5]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 Neuropeptide FF; F-8-F-NH2
编码 [99566-27-5]
别名 Neuropeptide FF; F-8-F-NH2
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） FLFQPQRF-NH2
序列（三字母缩写） H-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2?(trifluoroacetate salt)
基本描述 This peptide almost completely mimics the effects of the full length peptide (Neuropeptide S (human).
溶解度
分子量 1081.29
化学式 C54H76N14O10
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Neuropeptide FF; F-8-F-NH2 编码 [99566-27-5]
Figures Neuropeptide FF; F-8-F-NH2 编码 [99566-27-5]
Reference M.Xu et al., Peptides, 22, 33 (2001) C.Mollereau et al., Pharmacol. Rep., 63, 1061 (2011)
C端
N端
化学桥

FF-10502

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FF-10502 

FF-10502 是 Gemcitabine 的结构类似物，是一种嘧啶核苷抗代谢物。FF-10502 抑制 DNA 聚合酶 α 和 β (DNA polymerase α/β)。FF-10502 通过对休眠细胞的作用机制显示出有益的抗癌活性。

FF-10502

FF-10502 Chemical Structure

CAS No. : 184302-49-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells[1].

体外研究
(In Vitro)

FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC50s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Human pancreatic cancer cell lines (BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2)
Concentration: 0.1 nM to 10 μM
Incubation Time: 72 hours
Result: Inhibited the growth of pancreatic cancer cell lines.

体内研究
(In Vivo)

FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1].
Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg
Administration: Tail vein injection; once weekly; for 4 weeks
Result: Suppressed tumor growth in a dose-dependent manner in mice.

分子量

261.27

Formula

C9H12FN3O3S
CAS 号

184302-49-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FF-10502

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FF-10502 

FF-10502 是 Gemcitabine 的结构类似物，是一种嘧啶核苷抗代谢物。FF-10502 抑制 DNA 聚合酶 α 和 β (DNA polymerase α/β)。FF-10502 通过对休眠细胞的作用机制显示出有益的抗癌活性。

FF-10502

FF-10502 Chemical Structure

CAS No. : 184302-49-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells[1].

体外研究
(In Vitro)

FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC50s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Human pancreatic cancer cell lines (BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2)
Concentration: 0.1 nM to 10 μM
Incubation Time: 72 hours
Result: Inhibited the growth of pancreatic cancer cell lines.

体内研究
(In Vivo)

FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1].
Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg
Administration: Tail vein injection; once weekly; for 4 weeks
Result: Suppressed tumor growth in a dose-dependent manner in mice.

分子量

261.27

Formula

C9H12FN3O3S
CAS 号

184302-49-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FF-10502

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FF-10502 

FF-10502 是 Gemcitabine 的结构类似物，是一种嘧啶核苷抗代谢物。FF-10502 抑制 DNA 聚合酶 α 和 β (DNA polymerase α/β)。FF-10502 通过对休眠细胞的作用机制显示出有益的抗癌活性。

FF-10502

FF-10502 Chemical Structure

CAS No. : 184302-49-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells[1].

体外研究
(In Vitro)

FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC50s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Human pancreatic cancer cell lines (BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2)
Concentration: 0.1 nM to 10 μM
Incubation Time: 72 hours
Result: Inhibited the growth of pancreatic cancer cell lines.

体内研究
(In Vivo)

FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1].
Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg
Administration: Tail vein injection; once weekly; for 4 weeks
Result: Suppressed tumor growth in a dose-dependent manner in mice.

分子量

261.27

Formula

C9H12FN3O3S
CAS 号

184302-49-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shinji Mima, et al. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务